Evidence map›Paper›PMID 35253411›Full record

ArticleCancer communications (London, England)2022

Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition.

Christian Schneeweis, Zonera Hassan, Katja Ascherl, Matthias Wirth, Stella Koutsouli, Felix Orben, Lukas Krauß, Carolin Schneider, Rupert Öllinger, Oliver H Krämer and 5 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Journal of microbiology and biotechnology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Christian SchneeweisMedical Clinic and Polyclinic II, Klinikum rechts der Isar, Technical University Munich, Munich, 81675, Germany.
Zonera HassanMedical Clinic and Polyclinic II, Klinikum rechts der Isar, Technical University Munich, Munich, 81675, Germany.
Katja AscherlMedical Clinic and Polyclinic II, Klinikum rechts der Isar, Technical University Munich, Munich, 81675, Germany.
Matthias WirthDepartment of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, 12203, Germany.ORCID 0000-0002-8340-0872
Stella KoutsouliInstitute of Medical Psychology and Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Munich, 80336, Germany.
Felix OrbenMedical Clinic and Polyclinic II, Klinikum rechts der Isar, Technical University Munich, Munich, 81675, Germany.ORCID 0000-0002-2196-8702
Lukas KraußMedical Clinic and Polyclinic II, Klinikum rechts der Isar, Technical University Munich, Munich, 81675, Germany.ORCID 0000-0003-0062-8685
Carolin SchneiderMedical Clinic and Polyclinic II, Klinikum rechts der Isar, Technical University Munich, Munich, 81675, Germany.
Rupert ÖllingerInstitute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technical University Munich, Munich, 81675, Germany.
Oliver H KrämerDepartment of Toxicology, University of Mainz Medical Center, Mainz, 55131, Germany.
Roland RadInstitute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technical University Munich, Munich, 81675, Germany.
Maximilian ReichertMedical Clinic and Polyclinic II, Klinikum rechts der Isar, Technical University Munich, Munich, 81675, Germany.
Maria S RoblesInstitute of Medical Psychology and Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Munich, 80336, Germany.
Dieter SaurGerman Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, 69120, Germany.
Günter SchneiderMedical Clinic and Polyclinic II, Klinikum rechts der Isar, Technical University Munich, Munich, 81675, Germany.ORCID 0000-0003-1840-4508
TUM Klinikum · DEGerman Cancer Research Center · DELMU Klinikum · DEHumboldt-Universität zu Berlin · DEJohannes Gutenberg University Mainz · DETechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Pancreatic NeoplasmsTOR Serine-Threonine KinasesHumansSirolimusMTOR protein, humanSirolimusTOR Serine-Threonine Kinases

Identifiers

PMID35253411
PMCPMC9017755
OpenAlexW4220674856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.